Table 3.
Odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer comparing plasma prolactin ≥ 11 versus < 11 ng/mL by tumor expression of prolactin-related markers among postmenopausal women
| Tumor status | N (Cases) | Prolactin levels (ng/mL) | p-heterogeneity | |
|---|---|---|---|---|
| ≤ 11 | > 11 | |||
| All breast cancer | 577 | 1(Ref) | 1.37 (1.12, 1.67) | |
| Prolactin receptor | ||||
| Nucleara | ||||
| Negative | 406 | 1 (Ref) | 1.32 (1.05, 1.66) | 0.65 |
| Positive | 139 | 1 (Ref) | 1.45 (1.01, 2.07) | |
| Cytoplasmica | ||||
| Negative | 416 | 1 (Ref) | 1.32 (1.05, 1.65) | 0.60 |
| Positive | 129 | 1 (Ref) | 1.47 (1.01, 2.14) | |
| pSTAT5 | ||||
| Nucleara | ||||
| Negative | 394 | 1 (Ref) | 1.29 (1.03, 1.63) | 0.21 |
| Positive | 125 | 1 (Ref) | 1.69 (1.16, 2.46) | |
| Cytoplasmicb | ||||
| Negative | 213 | 1 (Ref) | 1.43 (1.07, 1.92) | 0.73 |
| Positive | 306 | 1 (Ref) | 1.34 (1.04, 1.73) | |
| Combined nuclear/cytoplasmic | ||||
| Both negative | 189 | 1 (Ref) | 1.45 (1.06, 1.97) | 0.53 |
| Both positive | 101 | 1 (Ref) | 1.78 (1.18, 2.68) | |
| One negative/one positive | 229 | 1 (Ref) | 1.35 (1.02, 1.80) | |
| pJAK2b | ||||
| Negative | 95 | 1 (Ref) | 1.52 (0.99, 2.33) | 0.68 |
| Positive | 409 | 1 (Ref) | 1.38 (1.10, 1.73) | |
Bolded values are statistically significant (p < 0.05)
Adjusted for age (continuous), age at menarche (continuous), BMI (continuous), benign breast disease (never, confirmed, unconfirmed), HT status (no, yes), and blood draw characteristics (fasting status and month of blood collection)
aA case was considered positive if one or more cores were scored 2 or 3
bCytoplasmic pSTAT5 and pJAK2 was scored positive if any core was scored 1 or higher